0001209191-19-031868.txt : 20190521 0001209191-19-031868.hdr.sgml : 20190521 20190521201438 ACCESSION NUMBER: 0001209191-19-031868 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190517 FILED AS OF DATE: 20190521 DATE AS OF CHANGE: 20190521 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: STACK DAVID M CENTRAL INDEX KEY: 0001204788 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21392 FILM NUMBER: 19843800 MAIL ADDRESS: STREET 1: THE MEDICINES CO STREET 2: 8 CAMPUS DRIVE CITY: PARSIPPANY STATE: NJ ZIP: 07054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMARIN CORP PLC\UK CENTRAL INDEX KEY: 0000897448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL, STREET 2: SHELBOURNE ROAD, BALLSBRIDGE CITY: DUBLIN STATE: L2 ZIP: 00000 BUSINESS PHONE: 353 1 6699 020 MAIL ADDRESS: STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL, STREET 2: SHELBOURNE ROAD, BALLSBRIDGE CITY: DUBLIN STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: AMARIN PHARMACEUTICALS PLC DATE OF NAME CHANGE: 20000201 FORMER COMPANY: FORMER CONFORMED NAME: ETHICAL HOLDINGS PLC DATE OF NAME CHANGE: 19930322 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-05-17 0 0000897448 AMARIN CORP PLC\UK AMRN 0001204788 STACK DAVID M C/O AMARIN PHARMA, INC. 1430 ROUTE 206 BEDMINSTER NJ 07921 1 0 0 0 Ordinary Shares 2019-05-17 4 M 0 13174 3.21 A 13174 D Ordinary Shares 2019-05-17 4 S 0 13174 18.0005 D 0 D Stock Option (Right to Buy) 3.21 2019-05-17 4 M 0 13174 0.00 D 2028-05-14 Ordinary Shares 13174 33799 D Stock Option (Right to Buy) 16.83 2019-05-20 4 A 0 9658 0.00 A 2029-05-20 Ordinary Shares 9658 9658 D Restricted Stock Units 0.00 2019-05-20 4 A 0 7428 0.00 A Ordinary Shares 7428 7428 D The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Please see the section titled "Remarks" below for additional information. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The stock option granted to the Reporting Person is fully vested as of the date hereof. On May 20, 2019, the Reporting Person was granted an option to purchase 9,658 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in 2020. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. On May 20, 2019, the Reporting Person was granted 7,428 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in such year. Not applicable. In the case of a Change of Control (as defined in the Plan), the grants described in this Form 4 vest in full. This number does not represent the aggregate number of Ordinary Shares of the Issuer this Reporting Person holds or has a right to acquire in the form of stock options and restricted stock units granted to such Reporting Person. The grants made on May 20, 2019 are made in accordance with the Issuer's previously disclosed non-employee director compensation program. /s/ Joseph Kennedy, by power of attorney 2019-05-21